Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389285 · ClinicalTrials.gov registry record · Phase 1
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
A Phase 1 study, sponsored by ZymoGenetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT00389285 is a Phase 1 study that has completed, run by ZymoGenetics. The registered enrollment target is 52 participants.
The verdict
NCT00389285, a Phase 1 study, has completed, sponsored by ZymoGenetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate whether recombinant IL-21 used in combination with sorafenib is safe for patients with metastatic renal cell carcinoma (RCC).
Interventions
- DRUG rIL-21 only
- DRUG rIL-21 + sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389285
The ClinicalTrials.gov registry entry for NCT00389285 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZymoGenetics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rIL-21 only is the first listed.
NCT00389285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389285 about?
NCT00389285 is a clinical study titled "Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma". The purpose of the study is to evaluate whether recombinant IL-21 used in combination with sorafenib is safe for patients with metastatic renal cell carcinoma (RCC).
What is the current status of trial NCT00389285?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2006-10. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00389285?
The interventions under investigation include: rIL-21 only (DRUG), rIL-21 + sorafenib (DRUG).
Who is sponsoring clinical trial NCT00389285?
This trial is sponsored by ZymoGenetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.